AUTHORS
Mahmoud R. Gaballa, MD, Hirono Iriuchishima, MD, PhD2, Emilie Chalayer, MD, PhD3, Kazuhito Suzuki, MD, PhD4, Kazuki Tanimoto, MD, PhD5, Thomas Pabst, MD6, Hisayuki Yokoyama, MD, PhD7, Tarek Abouzeid8, Vincent Camus, MD, PhD9, Anna Furlan, MD10, Max Hubmann11, Maria Alcala Peña12, Thomas Martin, MD13, Wolfgang Knauf14, Tomomi Toubai, MD, PhD15, Christina Tekle16, Karim Belaloui17, Chunfu Qiu18, Kosei Matsue, MD19, Francesca Fazio, MD, PhD20, Clemens Schulte21, Nobuhiro Tsukada, MD, PhD22
AFFILIATIONS
1 Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Department of Clinical Research, NHO, Shibukawa Medical Center, 383 Shiroi, Shibukawa, Gunma, Japan
3 Department of Clinical Hematology, CHU Saint-Étienne, Université Jean Monnet Saint-Étienne, INSERM CIC 1408, INSERM SAINBIOSE U1059, F-42023, Saint-Étienne, France
4 Division of Clinical Oncology and Hematology, Department of Internal Medicine, Jikei University School of Medicine, Tokyo, Japan
5 Hematology and Oncology Division, Japanese Red Cross Fukuoka Hospital, Fukuoka, Japan
6 Department of Medical Oncology, University Hospital Inselspital, Bern, Switzerland
7 Department of Hematology and Cell Therapy, Yamagata University Hospital, Yamagata, Japan
8 Hematology, Almouwasat Hospital, Dammam, Saudi Arabia
9 Department of Hematology, Centre Henri Becquerel, Rouen, France
10 Division of Hematology, Ospedale Ca’ Foncello di Treviso-ASL 2, Treviso, Italy
11 Praxis Hämatologie und Onkologie, Herrsching, Germany
12 Hematology Department, Hospital Regional Universitario de Málaga, Málaga, Spain
13 Department of Hematology, University of California San Francisco, San Francisco, California, United States
14 Centrum für Hämatologie und Onkologie Bethanien, Frankfurt, Germany
15 Department of Internal Medicine III, Division of Hematology and Cell Therapy, Yamagata University Faculty of Medicine, Yamagata, Japan, Hematology Division, Tokyo Metropolitan Cancer and Infectious Diseases Center, Komagome Hospital, Tokyo, Japan
16 Sanofi, Cambridge, MA, United States
17 Sanofi, Paris, France
18 Sanofi, Morristown, NJ, United States
19 Division of Hematology/Oncology, Kameda Medical Center, Chiba, Japan
20 Hematology Department of Translational and Precision Medicine, Sapienza University, Azienda Ospedaliero Universitaria Policlinico Umberto I Roma, Rome, Italy
21 Gemeinschaftspraxis für Hämatologie und Onkologie, Dortmund, Germany
22 Department of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan
ABSTRACT
Introduction: Isatuximab (Isa), an anti-CD38 monoclonal antibody, is approved in combination with pomalidomide and dexamethasone (Pd) and with carfilzomib and dexamethasone (Kd) for treatment of patients (pts) with relapsed/refractory multiple myeloma (RRMM), based on the phase 3 ICARIA-MM and IKEMA trials, respectively. The IONA-MM registry study evaluates the effectiveness and safety of isatuximab-Pd and isatuximab-Kd treatment (tx) in routine clinical practice. Here, we present results from the final analysis of IONA-MM.
Methods: IONA-MM is a multinational observational study of pts with RRMM treated with isatuximab in the real world. Pts ≥18 years of age with RRMM who received ≥1 prior line of therapy were prospectively or retrospectively enrolled. Treating physicians made the decision to initiate isatuximab before and independent of enrollment, and retrospectively enrolled pts were exposed to isatuximab within the past 3 months (mo). The isatuximab observation period began at isatuximab initiation; routine clinical assessments were performed 4 weeks after tx initiation and every 3 mo up to 30 days post‒tx discontinuation, at which point pts were followed up for ≤6 mo. Primary outcome measures included overall response rate (ORR), very good partial response or better rate (≥VGPR), and complete response or better rate (≥CR) within 12 mo, as well as duration of response (DOR), time to first response, progression-free survival (PFS), time to subsequent anti-MM therapy, quality of life, and treatment-emergent adverse events (TEAEs).
Results: As of 11 June 2026 (database lock date), 568 pts were enrolled, of whom 557 received ≥1 dose of isatuximab in combination with Pd (n=296), Kd (n=227), or other regimens (n=34), and had ≥1 post-baseline assessment. Pts in both the Isa-Pd and Isa-Kd arms had a median of 2 prior lines of therapy, with 58.8% and 51.5% refractory to lenalidomide (len), respectively. The median number of completed cycles of isatuximab was 6 for the Isa-Pd arm and 8 for the Isa-Kd arm, the median relative dose intensity of isatuximab was 81.3% (Isa-Pd) and 76.4% (Isa-Kd), and the median time in study was 12.9 (Isa-Pd) and 15.4 mo (Isa-Kd).
The ORR was 64.8% (160/247) in the Isa-Pd arm and 78.6% (154/196) in the Isa-Kd arm, of which 40.1% and 60.7% achieved ≥VGPR, and 16.6% and 24.0% achieved ≥CR, respectively. CR was the best response achieved in 12.6% of pts in the Isa-Pd arm and 18.4% of pts in the Isa-Kd arm. Len-refractory pts had comparable outcomes, especially among pts receiving Isa-Kd. ORR in this subgroup was 59.9% for Isa-Pd pts and 74.3% for Isa-Kd pts, of which ≥VGPR was 30.6% (Isa-Pd) and 58.1% (Isa-Kd), and ≥CR was 9.5% (Isa-Pd) and 22.9% (Isa-Kd). Among all pts, median DOR was 30.0 mo in the Isa-Pd arm and 28.6 mo in the Isa-Kd arm. Finally, the median PFS was 20.4 (95% CI: 14.0‒30.9) mo with Isa-Pd and 31.3 (95% CI: 22.5‒40.8) mo with Isa-Kd, with 28.4% of Isa-Pd pts and 35.0% of Isa-Kd pts free of disease progression at 60 mo.
In the safety population (N=567, enrolled pts who received ≥1 dose of isatuximab), all-grade TEAEs occurred in 244/299 (81.6%) and 202/233 (86.7%) pts receiving Isa-Pd and Isa-Kd, respectively, and grade ≥3 TEAEs occurred in 172 (57.5%) and 121 (51.9%) pts. Infections and infestations (system organ class) of any grade occurred in 48.5% and 54.1% of Isa-Pd and Isa-Kd pts (COVID-19: 16.4% [Isa-Pd], 17.2% [Isa-Kd]; pneumonia: 14.0%, 10.7%). Among adverse events of special interest, all-grade neutropenia occurred in 41.8% of Isa-Pd and 15.0% of Isa-Kd pts, and all-grade infusion-associated reactions occurred in 11.7% of pts receiving Isa-Pd and 20.6% of pts receiving Isa-Kd. TEAEs leading to definitive isatuximab discontinuation occurred in 16.7% of pts in the Isa-Pd arm and 15.0% of pts in the Isa-Kd arm.
Conclusions: In this final analysis of IONA-MM, Isa-Pd and Isa-Kd showed favorable effectiveness and a manageable safety profile in the real world, consistent with the findings of the pivotal ICARIA-MM and IKEMA trials. Outcomes in pts refractory to lenalidomide were consistent with those in the overall IONA-MM pt population. Finally, rates of TEAEs leading to discontinuation of isatuximab were low in both treatment arms. These results support the use of isatuximab in combination with Pd or Kd for patients with RRMM in the real world, including in specific patient subgroups.
DISCLOSURES
Mahmoud R. Gaballa, MD: Bristol Myers Squibb - Consultancy (Includes expert testimony); GLG - Consultancy (Includes expert testimony); Boxer Capital, LLC - Consultancy (Includes expert testimony); Bristol Myers Squibb/Celgene - Consultancy (Includes expert testimony); Arcellx - Consultancy (Includes expert testimony); Guidepoint - Consultancy (Includes expert testimony)